SLV 154 / Solve Therap - LARVOL DELTA

Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors (Businesswire) - "This latest funding follows a $75 million financing completed in December 2024, bringing Solve’s total capital raised to $321 million....Financing accelerates development of clinical-stage assets SLV-154 and SLV‑324, both featuring Solve’s CloakLink linker technology."

Financing • Solid Tumor

SLV-154 Treatment of Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Solve Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Cervical Cancer • Endometrial Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Sarcoma • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer

A Phase 1 Dose-Escalation Study of SLV 154 in Subjects with Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=70 | Not yet recruiting | Sponsor: Solve Therapeutics

New P1 trial • Breast Cancer • Cervical Cancer • Endometrial Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Sarcoma • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer